Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal
Proteostasis Therapeutics Inc. (mostly focused on orphan and neurodegenerative diseases caused by defects in protein folding, trafficking, and clearance) and Astellas Pharma Inc. will research and develop therapeutic candidates that modulate the unfolded protein response (UPR) pathway.
Drug Discovery Tools
- Drug Discovery Tools
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com